News - Merck KGaA, Erbitux


Current filters:

Merck KGaAErbitux

Popular Filters

Merck Serono’s Erbitux to be funded by CDF in England for mCRC


The UK’s Cancer Drugs Fund (CDF) says that Erbitux (cetuximab) can be used in the first line setting…

ErbituxFinancialHealthcareMerck KGaAMerck SeronoNorthern EuropeOncologyPharmaceuticalUK

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux


Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Merck KGaA improves guidance with strong third quarter results

Merck KGaA improves guidance with strong third quarter results


Germany’s Merck KGaA (MRK: DE) has posted solid organic revenue growth of 4.7% for the third quarter…

BiotechnologyErbituxEuropeFinancialMerck KGaAMerck SeronoPharmaceuticalRebif

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline


A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux


Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

News briefs from Threshold, Merck KGaA and GSK


US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial…

BiotechnologyErbituxEuropeGlaxoSmithKlineMerck KGaAMerck SeronoOncologyPharmaceuticalRegulationResearchSynflorixTH-302Threshold PharmaceuticalsVaccines

News briefs from Merck KGaA and Sanofi


German drug major Merck KGaA )MRK: DE) revealed this morning that its Phase III EXPAND trial, which assessed…

cilengitideErbituxManagementMerck KGaAMergers & AcquisitionsPharmaceuticalResearchSanofi

Adding cetuximab following colon cancer surgery does not improve disease-free survival


Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

Chinese colorectal cancer drug market forecast to grow to over $400 million in 2016


The colorectal cancer drug market in China will grow from a value of $261 million in 2011 to $404 million…

Asia-PacificAvastinErbituxMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix


In new draft guidance issued this week, UK drug watchdog the National Institute for Health and Clinical…

AmgenAvastinErbituxEuropeMerck KGaAOncologyPharmaceuticalPricingRegulationRocheVectibix

Erbitux and Gilenya added to Australia’s PBS listing


More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

Back to top